ES2610622T3 - Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol - Google Patents

Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol Download PDF

Info

Publication number
ES2610622T3
ES2610622T3 ES10764855.2T ES10764855T ES2610622T3 ES 2610622 T3 ES2610622 T3 ES 2610622T3 ES 10764855 T ES10764855 T ES 10764855T ES 2610622 T3 ES2610622 T3 ES 2610622T3
Authority
ES
Spain
Prior art keywords
cholesterol
treatment
regulation
microrna
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10764855.2T
Other languages
English (en)
Inventor
Anders M. Naar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2610622T3 publication Critical patent/ES2610622T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un ácido nucleico que es complementario de las SEQ ID NO. 1 o 2, para uso en el tratamiento terapéutico de un sujeto que necesite homeostasis de colesterol reduciendo la cantidad de colesterol en circulación en la sangre del sujeto; o aumentando la salida de colesterol intracelular y/o la producción de HDL en el hígado del sujeto.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
análisis por FPLC de suero agrupado como se ha descrito (Hyogo H, et al. (2002) J. Biol. Chem. 277: 34117). Las concentraciones de colesterol HDL en plasma aumentaron significativamente en animales tratados con LNAantisentido de miR33a en comparación con ratones tratados con controlLNA (Fig. 10A, B y Tabla 2). Por el contrario, no hubo ningún efecto significativo en las concentraciones en plasma de colesterol LDL, triglicéridos o niveles de
5 glucosa (Fig. 10BD y Tabla 2). En estos experimentos, tampoco hubo ninguna hepatotoxicidad aparente (AST/ALT en plasma) (Fig. 10E, F y Tabla 2). La elevación observada en HDL en plasma colesterol en respuesta a tratamiento con antisentido de LNAmiR33a es coherente con la regulación de la salida de colesterol dependiente de ABCA1 por miR33a in vivo.
10 Estos resultados confirman adicionalmente que la familia de SREBP de mamífero de factores de transcripción, reguladores clave de genes colesterogénicos y lipogénicos, son hospedadores para miARN conservados (miR33a/b) que actúan en concierto con los productos génicos de hospedador de SREBP para gobernar los niveles de colesterol intracelular y homeostasis de colesterol en vertebrados. La Fig. 10G representa un modelo para regulación coordinada de homeostasis de colesterol por miR33 y su producto génico hospedador SREBP. miR33 reprime la traducción de
15 ABCA1 dirigiéndose a su 3’ UTR. Esta etapa está coordinada con la expresión de SREBP, que activa la biosíntesis de colesterol y captación mediante transactivación de genes colesterogénicos. La acumulación de colesterol inhibe la ruta de SREBP, y activa la expresión de ABCA1, que se trasloca a la membrana celular y media en la salida de colesterol a apoAI y HDL.
20 Tabla 2
n
Tratamiento Colesterol [mg/dl] triglicéridos [mg/dl] Glucosa [mg/dl] ALT [UI/l] AST [UI/l]
antes
después antes después antes después antes después antes después
1
PBS 163,5 167 211 211 159 318 17 68 58 101
2
PBS 239,5 209 372 195 193 333 16 33 39 27
3
PBS 190,5 220 141 256 226 329 37 10 35 135
4
PBS 230 222 257 171 186 378 14 25 44 289
5
PBS 189,5 205 263 161 201 282 52 14 39 135
1
LNA 243 325 249 236 214 26 17 60 67
2
LNA 188 204 329 193 216 421 46 61 37 209
3
LNA 234,5 264 278 283 264 264 44 23 68 44
4
LNA 239 247 486 204 218 391 35 35 63 33
5
LNA 215,5 280 289 133 158 230 28 33 153 229
1
LC 206 157 308 224 275 72 26 128 142
2
LC 214,5 224 243 241 390 365 21 22 30 71
3
LC 180 223 384 134 160 233 18 22 54 150
4
LC 201 206 197 167 233 416 26 15 67 46
5
LC 210 186 238 373 286 299 47 17 68 52
Tabla 2. Tratamiento de ratones con una dieta de tipo occidental con ácido nucleico bloqueado (LNA)antímero de miR33a. Se midieron colesterol en suero total (A), triglicéridos en plasma (B), glucosa (C), AST (D) y ALT (E) en ratones alimentados con una dieta de tipo occidental antes y después de la inyección con PBS (vehículo),
25 oligonucleótidos antisentidoLNA dirigidos contra miR33a de ratón y oligonucleótidos de control de LNA mezclados (LC).
Como se representa en estos ejemplos, miembros de la familia de SREBP de mamífero de factores de transcripción, reguladores clave de genes colesterogénicos y lipogénicos, son hospedadores de miARN conservados (miR33a/b)
30 que actúan en concierto con los productos génicos hospedadores de SREBP para gobernar los niveles de colesterol intracelular y homeostasis de colesterol en vertebrados. miR33 ejerce control postranscripcional del transportador de colesterol ABCA1, con importantes consecuencias para el tráfico de colesterol in vitro y síntesis de HDL in vivo.
16
imagen15
imagen16

Claims (1)

  1. imagen1
ES10764855.2T 2009-03-31 2010-03-31 Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol Active ES2610622T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16504109P 2009-03-31 2009-03-31
US165041P 2009-03-31
PCT/US2010/029376 WO2010120508A2 (en) 2009-03-31 2010-03-31 Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders

Publications (1)

Publication Number Publication Date
ES2610622T3 true ES2610622T3 (es) 2017-04-28

Family

ID=42983071

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10764855.2T Active ES2610622T3 (es) 2009-03-31 2010-03-31 Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol

Country Status (6)

Country Link
US (3) US20120053229A1 (es)
EP (1) EP2414521B1 (es)
JP (1) JP5753838B2 (es)
DK (1) DK2414521T3 (es)
ES (1) ES2610622T3 (es)
WO (1) WO2010120508A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
CN103223177B (zh) * 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
US20110281933A1 (en) * 2010-05-13 2011-11-17 Saint Louis University Methods and compositions for the management of cardiovascular disease with oligonucleotides
JP2012019728A (ja) * 2010-07-14 2012-02-02 Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho ヒトａｂｃａ１遺伝子の転写を調整する作用を有する物質のスクリーニング方法
CA2808889A1 (en) * 2010-08-27 2012-03-01 New York University Mir-33 inhibitors and uses thereof
WO2012069059A1 (en) 2010-11-23 2012-05-31 Mirrx Therapeutics A/S Oligonucleotides for modulation of target rna activity
EP2663323B1 (en) 2011-01-14 2017-08-16 The General Hospital Corporation Methods targeting mir-128 for regulating cholesterol/lipid metabolism
US9241950B2 (en) 2011-04-28 2016-01-26 New York University MiR-33 inhibitors and uses thereof to decrease inflammation
US20150315595A1 (en) * 2012-03-12 2015-11-05 Santaris Pharma A/S Compositions and Methods for Modulation of ATXN3 Expression
WO2014012047A1 (en) * 2012-07-12 2014-01-16 University Of Louisville Research Foundation, Inc. Systems and methods for diagnosis, prognosis, and treatment of cancer
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
AU2014211406B2 (en) 2013-01-30 2019-07-18 Roche Innovation Center Copenhagen A/S LNA oligonucleotide carbohydrate conjugates
EP3104896B1 (en) 2014-02-14 2019-10-09 The Children's Hospital of Philadelphia Compositions and methods for treatment of cholestasis
JP6666002B2 (ja) 2015-10-07 2020-03-13 国立大学法人京都大学 Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
WO2021177267A1 (ja) * 2020-03-02 2021-09-10 田辺三菱製薬株式会社 ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療
EP4333907A4 (en) * 2021-05-07 2025-05-21 The Regents of the University of California Mirna inhibitors for preventing and treating aneurysms, hypertension, ards and other diseases associated with endothelial dysfunction

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035163T2 (de) * 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
CN100513570C (zh) * 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
US6835563B1 (en) * 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
EP1407774A1 (en) * 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
EP1791567B1 (en) * 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CA2584331A1 (en) * 2004-10-22 2006-05-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating pgc-1.beta. to treat lipid-related diseases and disorders
AU2006279906B2 (en) * 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
JP2009507918A (ja) * 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
WO2007109350A2 (en) * 2006-03-23 2007-09-27 California Institute Of Technology Modulation of innate immunity receptors' signaling by micrornas mir-146a and mir-146b
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
EP2054529B1 (en) * 2006-08-25 2014-03-26 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
US8673872B2 (en) * 2006-08-28 2014-03-18 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor(EGFR) involving miRNA
AU2007323469B2 (en) * 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
US20090005336A1 (en) * 2007-05-08 2009-01-01 Zhiguo Wang Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
WO2008142567A2 (en) * 2007-05-18 2008-11-27 Karolinska Institutet Innovations Ab Microrna molecules associated with inflammatory skin disorders
US20090082297A1 (en) * 2007-06-25 2009-03-26 Lioy Daniel T Compositions and Methods for Regulating Gene Expression
EP2182969B1 (en) * 2007-07-31 2016-11-16 The Board of Regents of The University of Texas System A micro-rna family that modulates fibrosis and uses thereof
US7812003B2 (en) * 2007-08-02 2010-10-12 Safe Stephen H Antisense microRNA and uses therefor
CA2716343A1 (en) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
EP2297338A2 (en) * 2008-05-30 2011-03-23 Ordway Research Institute, Inc. Methods for disease therapy

Also Published As

Publication number Publication date
EP2414521A2 (en) 2012-02-08
US20180119148A1 (en) 2018-05-03
JP5753838B2 (ja) 2015-07-22
WO2010120508A2 (en) 2010-10-21
EP2414521A4 (en) 2013-02-13
EP2414521B1 (en) 2016-10-26
WO2010120508A3 (en) 2011-03-17
DK2414521T3 (en) 2017-01-30
JP2012522509A (ja) 2012-09-27
US20120053229A1 (en) 2012-03-01
US20170233730A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
ES2610622T3 (es) Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol
Pan et al. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models
Hou et al. The potential atheroprotective role of plant MIR156a as a repressor of monocyte recruitment on inflamed human endothelial cells
Lin et al. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease
Guzmán et al. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease
Li et al. MicroRNA-214 suppresses gluconeogenesis by targeting activating transcriptional factor 4
Li et al. Identification of the biological affection of long noncoding RNA BC200 in Alzheimer’s disease
Li et al. Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages
Correia et al. Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism
Sun et al. LncRNA PCFL promotes cardiac fibrosis via miR-378/GRB2 pathway following myocardial infarction
Artuso et al. Mitochondrial DNA metabolism in early development of zebrafish (Danio rerio)
Bao et al. MicroRNA-297 promotes cardiomyocyte hypertrophy via targeting sigma-1 receptor
Shi et al. MicroRNA-128 targets myostatin at coding domain sequence to regulate myoblasts in skeletal muscle development
Jones et al. The role of CUGBP1 in age-dependent changes of liver functions
Shen et al. MicroRNA-200b regulates preadipocyte proliferation and differentiation by targeting KLF4
Lai et al. Liver-directed microRNA-7a depletion induces nonalcoholic fatty liver disease by stabilizing YY1-mediated lipogenic pathways in zebrafish
Hu et al. PLK1 promotes cholesterol efflux and alleviates atherosclerosis by up-regulating ABCA1 and ABCG1 expression via the AMPK/PPARγ/LXRα pathway
Huang et al. miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3
Wang et al. Exercise protects the heart against myocardial infarction through upregulation of miR-1192
Chen et al. TXNIP regulates myocardial fatty acid oxidation via miR-33a signaling
Xu et al. High fatty acids modulate P2X7 expression and IL-6 release via the p38 MAPK pathway in PC12 cells
Zhang et al. mmBCFA C17iso ensures endoplasmic reticulum integrity for lipid droplet growth
Li et al. Small RNA-big impact: exosomal miRNAs in mitochondrial dysfunction in various diseases
Li et al. Insulin suppresses the AMPK signaling pathway to regulate lipid metabolism in primary cultured hepatocytes of dairy cows
Zhou et al. Thymosin β4 inhibits microglia activation through microRNA 146a in neonatal rats following hypoxia injury